[Animal experimental studies using 19-nor-17 alpha-hydroxyprogesterone caproate (Gestenoroncapronat) with respect to a possible therapeutic application in prostatic adenoma].
D000726:Androgen Antagonists; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D005260:Female; D006908:Hydroxyprogesterones / Q000494:pharmacology / Q000627:therapeutic use*; D007016:Hypophysectomy; D007989:Libido; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D009929:Organ Size; D010060:Ovulation / Q000187:drug effects; D010121:Oxytocin / Q000037:antagonists & inhibitors; D011247:Pregnancy; D011270:Pregnancy, Animal; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D012669:Seminal Vesicles / Q000187:drug effects; D013094:Spermatozoa; D013737:Testis / Q000187:drug effects
D000726:Androgen Antagonists; D006063:Chorionic Gonadotropin; D006908:Hydroxyprogesterones; D010121:Oxytocin; D007986:Luteinizing Hormone
Tierexperimentelle Untersuchungen mit 19-nor-17 alpha-hydroxyprogesteron-capronat (Gestenoroncapronat) im Hinblick auf eine mögliche therapeutische Anwendung beim Prostataadenom.